You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

CLINICAL TRIALS PROFILE FOR MILNACIPRAN HYDROCHLORIDE

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for MILNACIPRAN HYDROCHLORIDE

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00098124 ↗	Study of Milnacipran for the Treatment of Fibromyalgia	Completed	Forest Laboratories	Phase 3	2004-11-01	Antidepressants of all varieties represent a common form of therapy for many chronic states including fibromyalgia. The majority of antidepressants increase the levels of serotonin or norepinephrine in the central nervous system. Milnacipran is a dual norepinephrine and serotonin reuptake inhibitor and may be effective in the treatment of fibromyalgia.
NCT00225511 ↗	Study Evaluating Effexor XR for Major Depression.	Completed	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 3	2004-06-01	Study Evaluating Effexor XR for Major Depression.
NCT00314249 ↗	Study of Milnacipran for the Treatment of Fibromyalgia	Completed	Cypress Bioscience, Inc.	Phase 3	2006-04-01	The purpose of this study was to demonstrate the efficacy and safety of milnacipran at a dosage of 100 mg/day in the treatment of the fibromyalgia syndrome or the pain associate with fibromyalgia.
NCT00314249 ↗	Study of Milnacipran for the Treatment of Fibromyalgia	Completed	Forest Laboratories	Phase 3	2006-04-01	The purpose of this study was to demonstrate the efficacy and safety of milnacipran at a dosage of 100 mg/day in the treatment of the fibromyalgia syndrome or the pain associate with fibromyalgia.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for MILNACIPRAN HYDROCHLORIDE

Condition Name

Chart
Table

Condition Name for MILNACIPRAN HYDROCHLORIDE
Intervention	Trials
Fibromyalgia	20
Depression	7
Chronic Pain	3
Primary Fibromyalgia	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for MILNACIPRAN HYDROCHLORIDE
Intervention	Trials
Fibromyalgia	28
Myofascial Pain Syndromes	27
Depression	7
Syndrome	6
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for MILNACIPRAN HYDROCHLORIDE

Trials by Country

Map
Table

Trials by Country for MILNACIPRAN HYDROCHLORIDE
Location	Trials
United States	212
Japan	19
Korea, Republic of	5
France	4
Portugal	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for MILNACIPRAN HYDROCHLORIDE
Location	Trials
California	12
New York	12
North Carolina	11
Florida	10
Ohio	9
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for MILNACIPRAN HYDROCHLORIDE

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for MILNACIPRAN HYDROCHLORIDE
Clinical Trial Phase	Trials
Phase 4	19
Phase 3	14
Phase 2/Phase 3	2
[disabled in preview]	7
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for MILNACIPRAN HYDROCHLORIDE
Clinical Trial Phase	Trials
Completed	32
Unknown status	11
Terminated	8
[disabled in preview]	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for MILNACIPRAN HYDROCHLORIDE

Sponsor Name

Chart
Table

Sponsor Name for MILNACIPRAN HYDROCHLORIDE
Sponsor	Trials
Forest Laboratories	29
Cypress Bioscience, Inc.	6
Samsung Medical Center	4
[disabled in preview]	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for MILNACIPRAN HYDROCHLORIDE
Sponsor	Trials
Other	54
Industry	43
NIH	2
[disabled in preview]	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.